FAJARDO, Puerto Rico, July 31 /PRNewswire/ -- Warner Chilcott Company, Inc. announced today that it has filed suit against Watson Laboratories, Inc. and Watson Pharmaceuticals, Inc. in the United States District Court for the District of New Jersey alleging infringement of Warner Chilcott’s U.S. patent that protects Loestrin(R) 24 Fe.
The lawsuit is in response to an Abbreviated New Drug Application filed by Watson with the FDA regarding Watson’s intent to market a generic version of Loestrin(R) 24 Fe prior to the expiration of Warner Chilcott’s U.S. Patent No. 5,552,394.
Warner Chilcott has full confidence in, and will continue to vigorously defend and enforce, its intellectual property rights protecting Loestrin(R) 24 Fe.
The Company
Warner Chilcott is a leading specialty pharmaceutical company focused on developing, manufacturing and marketing and selling branded prescription products in women’s healthcare and dermatology in the United States.
Forward Looking Statements
This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “may,” “might,” “will,” “should,” “estimate,” “project,” “plan,” “anticipate,” “expect,” intend,” “outlook,” “believe” and other similar expressions are intended to identify forward- looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.
The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate; our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; an increase in litigation, including product liability claims and patent litigation; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to successfully complete the implementation of a company-wide enterprise resource planning system without disrupting our business; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing and marketing new products, obtain regulatory approval and customer acceptance of those products, and continued customer acceptance of our existing products; and other risks detailed from time-to-time in our financial statements and other investor communications.
We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.
Warner Chilcott Company, Inc.
CONTACT: Paul Herendeen, Chief Financial Officer of Warner ChilcottCompany, Inc., +1-973-442-3200, pherendeen@wcrx.com
Web site: http://www.wclabs.com/
